1. Sci Rep. 2017 Jul 17;7(1):5596. doi: 10.1038/s41598-017-06101-6.

Effect of LDL cholesterol, statins and presence of mutations on the prevalence 
of type 2 diabetes in heterozygous familial hypercholesterolemia.

Climent E(1), Pérez-Calahorra S(2), Marco-Benedí V(2), Plana N(3), Sánchez R(4), 
Ros E(5), Ascaso JF(6), Puzo J(7), Almagro F(8), Lahoz C(9), Civeira F(2), 
Pedro-Botet J(10).

Author information:
(1)Lipid and Vascular Unit, Department of Endocrinology and Nutrition, Hospital 
del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain.
(2)Lipid Unit. Hospital Universitario Miguel Servet, IIS Aragón, Universidad de 
Zaragoza, Zaragoza, Spain.
(3)Unitat de Medicina Vascular i Metabolisme, Hospital Universitari Sant Joan, 
Institut d´Investigació Sanitaria Pere Virgili (IISPV), Reus, Tarragona, Spain.
(4)Lipid Unit, Servicio de Endocrinología y Nutrición, Hospital Universitario 
Insular de Gran Canarias, Instituto Universitario de Investigaciones Biomédicas 
y Sanitarias de la Universidad de Las Palmas de Gran Canarias, Las Palmas, 
Spain.
(5)Lipid Clinic, Endocrinology and Nutrition Service, Institut d'Investigacions 
Biomèdiques August Pi Sunyer, Hospital Clínic, Barcelona and CIBER 
Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos 
III (ISCIII), Madrid, Spain.
(6)Servicio de Endocrinología y Nutrición, Hospital Clínico Universitario, 
Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas 
Asociadas (CIBERDEM), Universitat de Valencia, Valencia, Spain.
(7)Lipid Unit. Hospital San Jorge, Huesca, Spain.
(8)Lipid Unit, Hospital Donostia, San Sebastián, Spain.
(9)Atherosclerosis Unit, Internal Medicine Department, Hospital Carlos III, 
Madrid, Spain.
(10)Lipid and Vascular Unit, Department of Endocrinology and Nutrition, Hospital 
del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain. 
86620@parcdesalutmar.cat.

Patients with heterozygous familial hypercholesterolemia (HeFH) have been 
reported to be less vulnerable to type 2 diabetes mellitus (T2DM), although the 
mechanism is unknown. The aims of the present study were to assess the effects 
of low density lipoprotein (LDL) cholesterol concentration and the presence of 
FH-causing mutations on T2DM prevalence in HeFH. Data were collected from the 
Dyslipidemia Registry of the Spanish Arteriosclerosis Society. Inclusion 
criteria were definite or probable HeFH in patients aged ≥18 years. T2DM 
prevalence in HeFH patients was compared with data of the general population. 
1732 patients were included. The prevalence of T2DM was lower in patients with 
HeFH compared with the general population (5.94% vs 9.44%; OR: 0.606, 95% CI 
0.486-0.755, p < 0.001). Risk factors for developing T2DM were male sex, age, 
body mass index, hypertension, baseline triglyceride levels and years on statin 
therapy. The prevalence of T2DM in HeFH patients was 40% lower than that 
observed in the general population. Gene mutations and LDL cholesterol 
concentrations were not risk factors associated with the prevalence of T2DM in 
patients with HeFH. The prevalence of T2DM in patients with HeFH was 40% lower 
than in the general population matched for age and sex.

DOI: 10.1038/s41598-017-06101-6
PMCID: PMC5514105
PMID: 28717233 [Indexed for MEDLINE]

Conflict of interest statement: The authors declare that they have no competing 
interests.